Cargando…
Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis
Viral infections cause many severe human diseases, being responsible for remarkably high mortality rates. In this sense, both the academy and the pharmaceutical industry are continuously searching for new compounds with antiviral activity, and in addition, face the challenge of developing greener an...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625736/ https://www.ncbi.nlm.nih.gov/pubmed/34832907 http://dx.doi.org/10.3390/ph14111125 |
_version_ | 1784606494554062848 |
---|---|
author | da Silva, Everton M. Vidal, Hérika D. A. Corrêa, Arlene G. |
author_facet | da Silva, Everton M. Vidal, Hérika D. A. Corrêa, Arlene G. |
author_sort | da Silva, Everton M. |
collection | PubMed |
description | Viral infections cause many severe human diseases, being responsible for remarkably high mortality rates. In this sense, both the academy and the pharmaceutical industry are continuously searching for new compounds with antiviral activity, and in addition, face the challenge of developing greener and more efficient methods to synthesize these compounds. This becomes even more important with drugs possessing stereogenic centers as highly enantioselective processes are required. In this minireview, the advances achieved to improve synthetic routes efficiency and sustainability of important commercially antiviral chiral drugs are discussed, highlighting the use of organocatalytic methods. |
format | Online Article Text |
id | pubmed-8625736 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86257362021-11-27 Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis da Silva, Everton M. Vidal, Hérika D. A. Corrêa, Arlene G. Pharmaceuticals (Basel) Review Viral infections cause many severe human diseases, being responsible for remarkably high mortality rates. In this sense, both the academy and the pharmaceutical industry are continuously searching for new compounds with antiviral activity, and in addition, face the challenge of developing greener and more efficient methods to synthesize these compounds. This becomes even more important with drugs possessing stereogenic centers as highly enantioselective processes are required. In this minireview, the advances achieved to improve synthetic routes efficiency and sustainability of important commercially antiviral chiral drugs are discussed, highlighting the use of organocatalytic methods. MDPI 2021-11-04 /pmc/articles/PMC8625736/ /pubmed/34832907 http://dx.doi.org/10.3390/ph14111125 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review da Silva, Everton M. Vidal, Hérika D. A. Corrêa, Arlene G. Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis |
title | Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis |
title_full | Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis |
title_fullStr | Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis |
title_full_unstemmed | Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis |
title_short | Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis |
title_sort | advances on greener asymmetric synthesis of antiviral drugs via organocatalysis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625736/ https://www.ncbi.nlm.nih.gov/pubmed/34832907 http://dx.doi.org/10.3390/ph14111125 |
work_keys_str_mv | AT dasilvaevertonm advancesongreenerasymmetricsynthesisofantiviraldrugsviaorganocatalysis AT vidalherikada advancesongreenerasymmetricsynthesisofantiviraldrugsviaorganocatalysis AT correaarleneg advancesongreenerasymmetricsynthesisofantiviraldrugsviaorganocatalysis |